Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease

NCT06198712 is registered in ClinicalTrials.gov with Forma Therapeutics, Inc. as lead sponsor.

NCT NCT06198712
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06198712 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
Lead sponsor
Forma Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
January 12, 2023
Completion date
August 8, 2029
Enrollment
95 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease